BMEA
NASDAQBiomea Fusion Inc.
Price$1.15-0.01 (-0.86%)
01:30 PM07:45 PM
News · 26 weeks28-75%
2025-12-142026-06-07
Mix1790d
- Other8(47%)
- SEC Filings6(35%)
- Insider2(12%)
- Earnings1(6%)
Latest news
25 items- PRBiomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association ("ADA") 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study•Translational data presented at ADA demonstrate icovamenib's potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes • Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced • Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist
- PRBiomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in ObesityCollaboration will Assess the Potential Impact of the Combination of Icovamenib and Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health and Metabolic OutcomesLate-Breaking Preclinical Findings at the American Diabetes Association Annual Meeting June 5-8 Highlighting Potential Mechanisms through which Icovamenib may Support Metabolic Health SAN CARLOS, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea," "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced a collaboration with the University of Leicester as part of the ongoing platform research study titled Investigating and Optimizing
- PRBiomea Fusion to Participate at Upcoming Investor ConferencesSAN CARLOS, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced that management will participate in the following investor conferences: H.C. Wainwright 4th Annual BioConnect Investor Conference: Biomea will participate in a fireside chat from 3:00–3:30 PM ET and in one-on-one meetings on May 19, 2026, in New York, NY.2026 Jefferies Global Healthcare Conference: Biomea will participate in a fireside chat from 8:10–8:40 AM ET and in one-on-one meetings on June 4, 2026, in New York, NY. An audio webcast of the fireside chats will be available here or by visiting the News & Ev
- SECSEC Form 10-Q filed by Biomea Fusion Inc.10-Q - Biomea Fusion, Inc. (0001840439) (Filer)
- SECBiomea Fusion Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Biomea Fusion, Inc. (0001840439) (Filer)
- PRBiomea Fusion Reports First Quarter 2026 Financial Results and Corporate HighlightsSuccessfully completed chronic toxicology studies for icovamenib, providing the nonclinical support for advancing to chronic clinical dosing, beyond the 12-week clinical dosing that has been used to dateTopline data reported from the Phase II COVALENT-112 clinical trial of icovamenib in type 1 diabetes ("T1D"), supporting proposed mechanism of actionFirst patients dosed in the Phase II COVALENT-211 and COVALENT-212 clinical trials of icovamenib in type 2 diabetes ("T2D"); both trials are on track with topline 26-week data expected in the fourth quarter of 2026The Phase I GLP-131 (BMF-650) obesity clinical trial is on track; initial 28-day weight reduction data expected in the second quarter
- PRBiomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific SessionsSAN CARLOS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced that three icovamenib abstracts have been selected for late-breaking poster presentations at the American Diabetes Association (ADA) 86th Scientific Sessions, taking place June 5–8, 2026 in New Orleans. The presentations include data from icovamenib, the Company's investigational oral menin inhibitor, across both type 1 and type 2 diabetes, highlighting its potential to improve beta cell function and support metabolic health. Presentation Details Title: Glycemic Improvements with Icovamenib in
- SECBiomea Fusion Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Biomea Fusion, Inc. (0001840439) (Filer)
- PRBiomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib TreatmentA 52% increase from baseline in mean C-peptide AUC at Week 12 in patients diagnosed within 0–3 years (n=5) receiving icovamenib 200 mg, with a clear dose response observed vs 100 mg (n=6)Persistence observed through Week 52, with mean C-peptide AUC largely preserved in 200 mg group (~7% decline from baseline) following only 12 weeks of dosingPreservation of C-peptide also observed in patients diagnosed between 3-15 years (n=9)Icovamenib was generally well tolerated across all dosing arms and demonstrated a favorable safety and tolerability profile through Week 52 Comprehensive dataset to be presented at the American Diabetes Association's (ADA) Scientific Sessions (abstract is preliminary un
- SECSEC Form DEF 14A filed by Biomea Fusion Inc.DEF 14A - Biomea Fusion, Inc. (0001840439) (Filer)
- INSIDERSEC Form 4 filed by Erdtmann Rainer M4 - Biomea Fusion, Inc. (0001840439) (Issuer)
- INSIDERSEC Form 4 filed by Hitchcock Michael J.M.4 - Biomea Fusion, Inc. (0001840439) (Issuer)
- PRBiomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care TherapiesCOVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients COVALENT-212 Phase II enrolling type 2 diabetes patients uncontrolled with a GLP-1 receptor agonist-based therapyTopline 26-week primary endpoint data from both Phase II studies anticipated 4Q 2026 SAN CARLOS, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, today announced that the first patient has been dosed in its newly initiated Phase II programs, COVALENT-211 and COVALENT-212, evaluating icovamenib in patients with type 2 diabetes ("T2D"), marking a key step in advancing icovame
- SECSEC Form 10-K filed by Biomea Fusion Inc.10-K - Biomea Fusion, Inc. (0001840439) (Filer)
- SECBiomea Fusion Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Biomea Fusion, Inc. (0001840439) (Filer)
- PRBiomea Fusion Reports Full Year 2025 Financial Results and Corporate HighlightsInitiated two Phase II trials COVALENT-211 and COVALENT-212 (icovamenib in type 2 diabetes) with 26-week primary endpoint data anticipated in the fourth quarter of 2026Completed 52-week follow-up from Phase II trial COVALENT-112 (icovamenib in type 1 diabetes) with data expected in the second quarter of 2026Initiated Phase I trial enrollment of GLP-131 (BMF-650 in obesity) with initial 28-day weight reduction data expected in the second quarter of 2026Projected cash runway into the first quarter of 2027 SAN CARLOS, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, toda
- PRBiomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026SAN CARLOS, Calif., March 14, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea," "Biomea Fusion," or the "Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced that Juan Pablo Frías, MD, delivered an oral presentation at the 19th International Conference on Advanced Technologies & Treatments for Diabetes ("ATTD") in Barcelona on March 14, 2026 highlighting positive 52-week follow-up results from the Company's Phase II COVALENT-111 study evaluating the efficacy, safety, and tolerability of icovamenib in patients with type 2 diabetes ("T2D"). "We are encouraged by the durability of icovamenib's effect observed nine months post-dosing at Week 52," said
- SECBiomea Fusion Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Biomea Fusion, Inc. (0001840439) (Filer)
- PRBiomea Fusion to Participate at Upcoming Investor ConferencesSAN CARLOS, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Company" or "Company management") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced that it will participate in the following upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference: Biomea will present virtually on February 26, 2026, at 10:00 AM (EDT). Company management will also meet with investors in one-on-one meetings during the conference.The Citizens Life Sciences Conference: Biomea will present at 2:50 PM (EDT) on March 10, 2026, in Miami, FL. Company management will also meet with investors in one-on-one meetings during the confer
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Biomea Fusion Inc.SCHEDULE 13G/A - Biomea Fusion, Inc. (0001840439) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Biomea Fusion Inc.SCHEDULE 13G/A - Biomea Fusion, Inc. (0001840439) (Subject)
- INSIDERErdtmann Rainer M decreased direct ownership by 21% to 572,427 units (SEC Form 5)5 - Biomea Fusion, Inc. (0001840439) (Issuer)
- SECBiomea Fusion Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Biomea Fusion, Inc. (0001840439) (Filer)
- ANALYSTRodman & Renshaw initiated coverage on Biomea Fusion with a new price targetRodman & Renshaw initiated coverage of Biomea Fusion with a rating of Buy and set a new price target of $8.00
- PRBiomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 MilestonesAdvancing icovamenib toward late-stage clinical development in two Phase II clinical trials in patients with insulin-deficient type 2 diabetes ("T2D") and in T2D patients currently failing glucagon-like peptide-1 ("GLP-1") based therapiesSuccessfully completed icovamenib food-effect study, establishing optimal dosing conditions to support late-stage clinical studies Successfully completed icovamenib chronic toxicology studies, supporting potential flexibility to evaluate clinical dosing beyond the validated 12-week regimenAdvancing BMF-650 through clinical development as an oral next-generation GLP-1 receptor agonist candidate designed to deliver effective and patient-friendly metabolic bene
BMEA FAQ
7 questionsWhat does Biomea Fusion Inc. do?
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of MENIN, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was founded in 2017 and is headquartered in Redwood City, California.Where does BMEA stock trade?
Biomea Fusion Inc. (BMEA) is listed on NASDAQ.What sector and industry is BMEA in?
Biomea Fusion Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Biomea Fusion Inc. go public?
Biomea Fusion Inc. (BMEA) completed its IPO in 2021.What are analysts saying about BMEA?
Biomea Fusion Inc. has had 8 recent analyst actions on file. The most recent action was from Rodman & Renshaw: Buy with a $800.00 price target on 2026-01-13. Recent price targets range from $500.00 to $2500.00.What companies are similar to BMEA?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare BMEA side-by-side with any of them on Quantisnow.How can I track BMEA on Quantisnow?
Quantisnow aggregates Biomea Fusion Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BMEA to receive live email and push alerts on every new disclosure.